[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-419805-105":59,"doc-detail-419805-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","mogamulizumab-plus-etoposide-in-the-management-of-mycosis-fungoides-with-blood-involvement-a-case-report","Mogamulizumab plus etoposide in the management of mycosis fungoides with blood involvement: a case report","","Mycosis fungoides (MF) and Sézary syndrome are primary cutaneous T-cell lymphomas with variable courses and prognoses. A male patient developed scaly, itchy, painful trunk and upper-extremity patches in 2012 that progressed to erythroderma with blood involvement. Multiple skin-directed and systemic therapies were attempted, including methotrexate (partial response, stopped for elevated transaminases). After progression on bexarotene and gemcitabine/CHOP, mogamulizumab started in May 2020 produced initial skin and blood response, with later remission achieved by adding etoposide and prednisone. Progression recurred, and transformation to large cell CD30+ occurred in October 2022, followed by extracorporeal photopheresis, brentuximab vedotin, and topical steroids. The patient died of sepsis in February 2023.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mogamulizumab-plus-etoposide-in-the-management-of-mycosis-fungoides-with-blood-involvement-a-case-report/419805/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mogamulizumab-plus-etoposide-in-the-management-of-mycosis-fungoides-with-blood-involvement-a-case-report/419805.png","ImageObject",300,407,{"name":92,"@type":93},"Blitz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What disease was described in the case report?","Question",{"text":113,"@type":114},"The case involved mycosis fungoides with blood involvement, which progressed from skin patches to erythroderma and later developed large cell CD30+ transformation.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which treatments were tried before mogamulizumab?",{"text":118,"@type":114},"The patient underwent multiple skin-directed and systemic therapies, including methotrexate, bexarotene, gemcitabine, and CHOP chemotherapy, with eventual progression.",{"name":120,"@type":111,"acceptedAnswer":121},"How did the patient respond to mogamulizumab, and what changed after progression?",{"text":122,"@type":114},"Mogamulizumab produced an initial good response in skin and blood. After skin progression, remission was achieved by continuing mogamulizumab with etoposide and prednisone; later progression led to a treatment strategy change to extracorporeal photopheresis, brentuximab vedotin, and topical steroids.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},419805,1790740491,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Mogamulizumab plus etoposide in the management of mycosis fungoides with blood involvement: a case report  \nDaniel Nieto Rodríguez and Elena Sendagorta  \nTherAdv Hematol 2026, Vol. 17: 1–5  \nDOI: 10. 1177/ 20406207251388057  \n© The Author(s), 2026. Article reuse guidelines: [sagepub.com/journals](sagepub.com/journals)permissions  \nAbstract: Mycosis fungoides (MF) and Sézary syndrome are primary cutaneous T-cell lymphomas with widely varying courses of disease and prognosis. Here, we report the case of a patient with MF with blood involvement who experienced many lines of skin-directed and systemic therapies throughout their disease course. The male patient presented with scaly, itchy, and painful patches on his trunk and upper extremities in 2012 and was diagnosed with MF, which progressed to erythroderma with blood involvement. Various skin-directed therapies were prescribed; however, in 2014, progression of skin lesions ensued. The patient achieved a partial response with methotrexate but discontinued after ~12 months due to elevated transaminases. Following treatment with bexarotene then gemcitabine, CHOP chemotherapy was initiated in December 2019, but, after a period of partial skin response, the patient relapsed with progression of skin lesions. Mogamulizumab was initiated in May 2020 (1 mg/kg intravenously on days 1, 8, 15, and 22 of the first 28-day cycle, then on days 1 and 15 of subsequent cycles) with a good initial response in skin and blood. Disease progression in the skin occurred in December 2020; mogamulizumab was continued, and the patient achieved remission with the addition of etoposide and prednisone in August 2021. Onset of progression occurred in July 2022, which did not respond to repeat combination treatment. In October 2022, the patient was diagnosed with large cell CD30 + transformation, and the therapeutic approach was changed to extracorporeal photopheresis, brentuximab vedotin, and topical steroids. The patient died in February 2023 due to sepsis. Our experience adds to the limited evidence that mogamulizumab may be continued in combination with etoposide following disease progression in patients with MF with blood involvement; however, more research is needed on the efficacy and safety of this approach.  \nKeywords: case report, comorbidities, mogamulizumab, mycosis fungoides, treatmentrefractory  \nReceived: 26 April 2024; revised manuscript accepted: 29 September 2025.  \nBackground  \nMycosis fungoides (MF) and Sézary syndrome (SS) are types of primary cutaneous lymphoma, a heterogeneous group of T-cell and B-cell nonHodgkin lymphomas that present in the skin.1 Early-stage MF often has a relatively indolent disease course, with possible progression of lesions, whereas progression to or initial presentation with advanced-stage (IIB–IVB) MF or SS confers a worse prognosis, often characterized by significant involvement of the blood, tumors, and/or  \nerythroderma, lymphadenopathy, and shorter survival.1–4 Patients with early-stage MF are often treated primarily with skin-directed therapies (SDTs), whereas those with more advanced or treatment-refractory MF, or SS, generally require systemic treatment, alone or in combination with SDTs. 1,5  \nMogamulizumab is a defucosylated, humanized IgG1 monoclonal antibody against the C-C chemokine receptor 4 (CCR4) approved in Europe  \nCorrespondence to:  \nDaniel Nieto Rodríguez Elena Sendagorta  \nHospital Universitario La Paz, Paseo de la Castellana, 261, Madrid 28046, Spain  \nDaniel. nieto@salud. [madrid.org](madrid.org)[ ](madrid.org)elenamaria.sendagorta@ [salud.madrid.org](salud.madrid.org)  \n[journals.sagepub.com/home/tah](journals.sagepub.com/home/tah) 1  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License  \n([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and dist","cbCaif21pw1c6eHJ","https://ap.wps.com/l/cbCaif21pw1c6eHJ","pdf",543650,"English","# Case report title\n## Disease course and prior therapies\n## Mogamulizumab dosing and response\n## Progression, transformation, and subsequent treatment","[{\"question\":\"What disease was described in the case report?\",\"answer\":\"The case involved mycosis fungoides with blood involvement, which progressed from skin patches to erythroderma and later developed large cell CD30+ transformation.\"},{\"question\":\"Which treatments were tried before mogamulizumab?\",\"answer\":\"The patient underwent multiple skin-directed and systemic therapies, including methotrexate, bexarotene, gemcitabine, and CHOP chemotherapy, with eventual progression.\"},{\"question\":\"How did the patient respond to mogamulizumab, and what changed after progression?\",\"answer\":\"Mogamulizumab produced an initial good response in skin and blood. After skin progression, remission was achieved by continuing mogamulizumab with etoposide and prednisone; later progression led to a treatment strategy change to extracorporeal photopheresis, brentuximab vedotin, and topical steroids.\"}]","Mogamulizumab plus etoposide in the management of mycosis fungoides with blood involvement: a case report | PDF",1790618369,13]